Artificial Intelligence

Are Workplace Chats Becoming the Next Layer of AI Memory?

As workplace knowledge spreads across chats, AI firms are building systems that can structure, retrieve and preserve it over time.

Updated

May 11, 2026 5:24 PM

A messaging app on a phone. PHOTO: ADOBE STOCK

Votee AI, an enterprise AI company headquartered in Hong Kong, has partnered with its Toronto-based research lab Beever AI to launch Beever Atlas. The new platform is designed to turn workplace chats into searchable knowledge that AI systems can retrieve and understand.

The release focuses on a growing issue inside organisations. Much of today’s workplace knowledge now exists inside chat platforms such as Slack, Microsoft Teams, Discord and Telegram. Important discussions, project decisions and technical information often disappear into long message histories that are difficult to search later.

Beever AI developed the platform to organise those conversations into a structured system for AI assistants. The software connects with Telegram, Discord, Mattermost, Microsoft Teams and Slack, then converts conversations into linked records of people, projects, files and decisions.

The collaboration combines Votee AI’s enterprise infrastructure work with Beever AI’s research around AI memory systems. The companies are releasing two versions of the product. The open-source edition is aimed at individual developers, researchers and creators. The enterprise edition is designed for banks, government agencies and larger organisations with stricter security requirements.

The release also reflects a broader shift happening across the AI industry. Companies are increasingly looking at how AI systems store and retrieve long-term knowledge, rather than relying solely on large context windows or search-based retrieval.

Earlier this year, OpenAI founding member and former director of AI at Tesla  Andrej Karpathy discussed the growing need for what he described as “LLM Knowledge Bases.” He argued that AI systems need structured and evolving memory rather than depending only on context windows and vector search.

Beever Atlas approaches that problem through workplace communication. Instead of focusing mainly on uploaded files, the system is designed around conversations that happen daily across team chat platforms. It can also process images, PDFs, voice notes and video files within the same searchable system.

The companies say the software is designed to work directly with AI assistants and coding tools such as Cursor, AWS Kiro and Qwen Code. Integrations for OpenClaw and Hermes Agent are expected later in 2026.

Pak-Sun Ting, Co-Founder and CEO of Votee AI  said: "Hong Kong has always been known for property and finance. Beever Atlas is proof that world-class AI infrastructure can emerge from an HK-headquartered company and be shared openly with the world. Every growing organization faces the same silent liability: conversational knowledge loss. Beever Atlas turns this perishable resource into a compounding organizational asset."

A large part of the enterprise version focuses on privacy and access control. The system mirrors permissions from Slack and Microsoft Teams so users can only retrieve information they are already authorised to access. Permission updates are reflected automatically when access changes inside company systems.

The enterprise edition also includes audit logs, encryption controls and data retention settings for organisations handling sensitive internal data. Companies can run the software entirely inside their own infrastructure using Docker and connect it to their preferred AI models through LiteLLM.

The companies argue that organising information is more useful than simply storing chat archives. Jacky Chan Co-Founder and CTO of Votee AI said: "The key technical decision was to treat agent memory as a knowledge engineering problem, not a retrieval problem. Structure beats similarity — a typed graph of who works on what is more useful to an AI than vector search over a Slack archive."

The software also includes protections against prompt injection attacks and systems designed to reduce hallucinated responses. According to the companies, the AI is designed to return “I don't know” with citations when confidence is low instead of generating unsupported answers.

As workplace communication becomes increasingly fragmented across chat platforms, companies are beginning to treat internal conversations as information that AI systems can organise, retrieve and build on. Beever Atlas reflects a broader push to turn everyday workplace communication into long-term organisational memory.

Keep Reading

Artificial Intelligence

DeepCyte Raises US$1.5M to Use AI and Single-Cell Analysis to Predict Drug Toxicity

A new approach examines how individual cells respond to drugs, aiming to identify risks earlier in development.

Updated

May 1, 2026 2:25 PM

Close up of a capsule blister pack. PHOTO: UNSPLASH

DeepCyte, a startup in the drug development space, is focusing on a long-standing problem: why drugs that appear safe in early testing still fail in clinical trials or are withdrawn later due to toxicity. DeepCyte has launched with US$1.5 million in seed funding to build tools that detect and explain the harmful effects of drugs at much earlier stages.

The startup’s approach focuses on how individual cells respond to a drug. Instead of analysing cells in bulk, it studies them one by one. This helps capture differences in how cells react, which are often missed in traditional testing methods.

Drug toxicity remains one of the main reasons for failure in drug development. Methods such as animal testing and bulk cell analysis do not always reflect how human cells behave. This gap has pushed the industry to look for more reliable and human-relevant ways to test drug safety.

DeepCyte combines cell-level data with artificial intelligence. Its platform, MetaCore, studies what is happening inside individual cells by capturing detailed molecular information. This data is used to build large datasets that can train AI models.

Additionally, the company has developed an AI system called DeeImmuno. It is designed to predict whether a drug could be toxic and identify the biological reasons behind it. In internal testing on 100 drugs, the system identified different types of toxicity and their underlying mechanisms with a reported accuracy of 94 percent.

The focus on explaining why a drug is toxic, not just whether it is, reflects a broader shift in the industry. Regulators such as the U.S. Food and Drug Administration and the European Medicines Agency have been encouraging methods that rely more on human cell data and clearer biological evidence. The seed funding will be used to develop and scale these tools. The company aims to help drug developers make earlier decisions, which could reduce costly failures in later stages. Whether tools like this become widely used will depend on how they perform in real-world settings. For now, DeepCyte’s approach highlights a growing effort to make drug testing more precise by focusing on how drugs affect cells at the most detailed level.